Womack v. EVOL Nutrition Associates, Inc.

CourtDistrict Court, N.D. New York
DecidedDecember 14, 2021
Docket6:21-cv-00332
StatusUnknown

This text of Womack v. EVOL Nutrition Associates, Inc. (Womack v. EVOL Nutrition Associates, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Womack v. EVOL Nutrition Associates, Inc., (N.D.N.Y. 2021).

Opinion

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF NEW YORK

DUANE WOMACK, individually and on behalf of all others similarly situated, 6:21-cv-00332 (BKS/TWD) Plaintiff,

v.

EVOL NUTRITION ASSOCIATES, INC., d/b/a Red Dawn Energy, a Georgia Corporation,

Defendant.

Appearances: For Plaintiff: Trenton R. Kashima Sommers Schwartz, P.C. 402 West Broadway, Ste. 1760 San Diego, CA 92101

Jan M. Smolak Michaels & Smolak, P.C. 17 East Genesee St., Ste. 401 Auburn, NY 13021

For Defendant: Phillip A. Oswald Rupp Baase Pfalzgraf Cunningham LLC 227 Washington St., Ste. 1C Saratoga Springs, NY 12866

Kevin J. Federation Rupp Baase Pfalzgraf Cunningham LLC 400 Powers Bldg. 16 West Main St. Rochester, NY 14614 Hon. Brenda K. Sannes, United States District Judge: MEMORANDUM-DECISION AND ORDER I. INTRODUCTION Plaintiff Duane Womack brings this proposed class action against Defendant EVOL Nutrition Associates, Inc. seeking damages, restitution, injunctive relief, costs, and attorney’s fees for Defendant’s allegedly unfair and deceptive trade practices in the marketing, distribution,

and retail of its “Sleep Walker” and “Red Dawn” Products (the “Products”). (Dkt. No. 1). Plaintiff asserts his claim on behalf of himself and others similarly situated who purchased the Products, alleging violation of the Unfair and Deceptive Trade Practices Act, New York General Business Law (“NYGBL”) § 349 et. seq. (Id.). Defendant moves to dismiss the complaint under Rules 4(m), 12(b)(5), (6), and 60(b) of the Federal Rules of Civil Procedure for failure to timely serve the summons and complaint without good cause, and failure to state a claim on which relief can be granted. (Dkt. No. 17). Plaintiff opposes Defendant’s motion. (Dkt. No. 18). For the following reasons, Defendant’s motion to dismiss is granted. II. COMPLAINT1 A. “Sleep Walker” and “Red Dawn” Products

Defendant manufactures, markets, and retails the Products as “dietary supplements that provide extra energy and enhance[] the consumer’s mood.” (Dkt. No. 1, ¶ 1). The Products are sold “in capsule form, as two ounce (60ml) liquid single-serving ‘shots,’ or in larger four to sixteen ounce multi-serving bottles,” and are offered in several flavors. (Id. ¶ 9). Defendant

1 The facts are drawn from the Complaint. The Court assumes that all well-pleaded facts are true and draws all reasonable inferences in Plaintiff’s favor. Faber v. Metropolitan Life Ins. Co., 648 F.3d 98, 104 (2d Cir. 2011). markets the Products as energy drinks, such that they compete with coffee and other caffeinated drinks. (/d. § 1). Defendant “markets these Products as safe and effective.” (/d. § 10).

(ll

me)

ahgae 2 =. tt V Gyn ate een ie y' h nm

However, the Products contain “Beta-phenyl-gamma-aminobutyric acid,” otherwise known as “Phenibut” or “GABA.” (/d. § 2). Phenibut is a “drug” that works by “mimicking the brain chemical called gamma-aminobutyric acid, which is a calming neurotransmitter,” and is “used to treat insomnia, depression, stuttering, vestibular disorder, irregular heartbeat, and post- traumatic stress disorder in Russia, Ukraine, Belarus and Latvia.” Ud. □□ 10, 11). “There is no good scientific evidence . . . to support Phenibut’s treatment of these conditions.” (Ud. ¥ 10). Phenibut instead “seems to be used primarily as a recreational drug.” (/d.). Phenibut has many side effects. It can cause “dizziness, nausea, poor balance, and fatigue” when taken orally, and, when taken in large doses, it can cause “trouble breathing, feelings of electric shocks in the arms and legs, and unconsciousness.” (/d. J 11). Consumers of Phenibut report feeling “unwell” after a single serving, and feeling “uneas[iness], nausea, and other hangover like symptoms for up to twenty-four hours” after consumption. (/d. § 22). Long-

term, Phenibut can cause “depression and fatigue.” (Id. ¶ 12). It can also cause dependence, even after one use. (Id. ¶ 11). “People who use Phenibut regularly, and then stop taking it, may experience withdrawal symptoms,” including “decreased appetite, nausea, muscle aches, anxiety, agitation, trouble sleeping, and seizures.” (Id. ¶ 12). There is “little scientific research” about

what constitutes a safe dosage of Phenibut for adults, and “Phenibut has been banned in Hungary, Lithuania, Italy, and Australia” due to concerns about withdrawal and overdose. (Id. ¶¶ 12, 14). Phenibut is not approved for use in the United States. (Id. at ¶ 13). On April 10, 2019, the Food and Drug Administration (“FDA”) sent Defendant a warning letter, noting that Phenibut is not a dietary ingredient under the Federal Food, Drug and Cosmetic Act (“FDCA”), and therefore that “[d]eclaring phenibut in [its] product labeling as a dietary ingredient cause[d its] products to be misbranded under [the FDCA] in that the labeling is false or misleading in any particular.” (Id. ¶ 20). Phenibut is not “generally recognized as safe” (“GRAS”), and therefore requires “premarket approval,” which Defendant has not sought, rendering the Products

misbranded “under federal and New York State law.” (Id. ¶ 20). The Products therefore “may not be sold in the United States.” (Id. ¶ 21). Yet after receiving the FDA warning letter, “Defendant continued to market the Product[s] with Phenibut.” (Id. ¶ 42). Defendant markets the Products to consumers without disclosing the dangers of Phenibut or the fact that Phenibut is “not approved for use in the United States.” (Id. ¶ 13). The Products’ labels indicate that they contain a “Proprietary Blend” or “Proprietary Focus/Mood Blend.” (Id. ¶ 2). The labels make claims including “increase focus & elevate mood,” “Stress & Anxiety Relief,” “Better Mileage™ for Brain and Body,” and “EXTRA ENERGY! EXTRA MOOD ENHANCEMENT!” (Id. ¶ 9). Defendant “mislead consumers about the immediate health dangers and risk of addiction caused by Phenibut in the Products” by marketing them as energy drinks and failing to adequately warn consumers of the dangers of Phenibut, which “Defendant knew or should have known might result from consuming the Products.” (Id. ¶ 23). B. Plaintiff’s Purchase and Use of the Products Plaintiff Duane Womack, a resident of Rome, New York and citizen of New York,

purchased several of Defendant’s Sleep Walker Products “in the last four years, including at a Speedway store located in New York on or about June 2020.” (Id. at ¶ 7). He believed that the Products would be safe and would provide him with an energy boost. (Id.). Plaintiff did not know that the Products “contained a dangerous and unapproved ingredient” or that they were “misbranded and adulterated dietary supplements.” (Id. ¶¶ 4, 26). If he had known, he would not have purchased the Products, “or would have paid less.” (Id. ¶ 4). After consuming the Products, Plaintiff experienced side effects including “dizziness, nausea, or fatigue for over twelve hours.” (Id. ¶ 7). The side effects Plaintiff experienced “were so pronounced, that Plaintiff did not finish the remaining Products that he purchased.” (Id.). Plaintiff proposes to bring this action on behalf of himself and the following class under

Federal Rule of Civil Procedure 23(a), (b)(2) and/or (b)(3): All persons in state of New York and who purchased the Sleep Walker (sold in both liquid and capsule forms) and Red Dawn Liquid Products between March 23, 2018 and the present.

(Id. ¶ 28). III. MOTION TO DISMISS—Fed. R. Civ. P. 60

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Henderson v. United States
517 U.S. 654 (Supreme Court, 1996)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Faber v. Metropolitan Life Insurance
648 F.3d 98 (Second Circuit, 2011)
Zapata v. City of New York
502 F.3d 192 (Second Circuit, 2007)
Stone Exchange, Inc. v. Surface Technology Corp.
605 S.E.2d 404 (Court of Appeals of Georgia, 2004)
Oswego Laborers' Local 214 Pension Fund v. Marine Midland Bank, N. A.
647 N.E.2d 741 (New York Court of Appeals, 1995)
Woods v. Maytag Co.
807 F. Supp. 2d 112 (E.D. New York, 2011)
Stutman v. Chemical Bank
731 N.E.2d 608 (New York Court of Appeals, 2000)
Preston v. New York
223 F. Supp. 2d 452 (S.D. New York, 2002)
Bildstein v. Mastercard International Inc.
329 F. Supp. 2d 410 (S.D. New York, 2004)
Nature's First Inc. v. Nature's First Law, Inc.
436 F. Supp. 2d 368 (D. Connecticut, 2006)
Darden v. Daimlerchrysler North America Holding Corp.
191 F. Supp. 2d 382 (S.D. New York, 2002)
Davis v. Frederick J. Hanna & Associates, P.C.
506 F. Supp. 2d 1322 (N.D. Georgia, 2007)
Mende v. Milestone Technology, Inc.
269 F. Supp. 2d 246 (S.D. New York, 2003)
Orlander v. Staples, Inc.
802 F.3d 289 (Second Circuit, 2015)
Weisblum v. Prophase Labs, Inc.
88 F. Supp. 3d 283 (S.D. New York, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
Womack v. EVOL Nutrition Associates, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/womack-v-evol-nutrition-associates-inc-nynd-2021.